Drugs / ION356
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06150716 | Apr 2024 → Jun 2028 expected | Pelizaeus-Merzbacher spectrum disorder | Ionis Pharmaceuticals, Inc. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ION356 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06150716 ↗ |
| Route | Intrathecal | “Administered as intrathecal (IT) injection.” NCT06150716 ↗ |